The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

The company now expects vaccine sales to decline by low single digits versus last year. During the third quarter, sales of GSK’s shingles vaccine dropped by 7% compared to the same period in ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GlaxoSmithKline has filed its shingles vaccine in Europe, as it seeks to boost sales with a new wave of drugs. The EU filing of Shingrix follows a US filing last month for the drug, which analysts ...

GSK stock plunged Wednesday after sales of its RSV vaccine, Arexvy, skidded and widely missed Wall Street's expectations.

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

GSK plc GSK reported third-quarter 2024 core ... This was due to lower sales of RSV and shingles vaccines in the United States. All growth rates mentioned below are on a year-over-year basis ...